An observational study in Mild Cognitive Impairment, Alzheimer's Disease and Dementia, sponsored by Peking University. Completed at 28 sites in China. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2017-07-25.
Sponsored by Peking University · Observational
There are guidelines on the management of AD in China, the evidence adopted in the guidelines are mostly from the trials conducted in other countries due to very limited Chinese data available for local systematic review. Therefore, more local evidence on dementia care is needed for the development of an evidence-based guideline appropriate for people living in China. Meanwhile, the inadequate implementation of the current AD guideline, which results in the low diagnostic rate and high diagnostic leakage, may bring about extra barriers for AD patients to access dementia care service in different areas nationwide. However, there is no data on the clinical pathway about how physicians follow the dementia guideline in the routine practice.
Therefore, research is needed to learn clinical diagnostic process and treatment patterns of physicians to people with AD in routine practice and help address the low accurate rate of AD clinical diagnosis and low anti-dementia drug prescription in the real world and support guideline development.
Outpatients who are visiting memory clinics and who are judged by physicians with clinically significant cognitive impairment will be invited to join the study during the study recruiting period (with informed consent signed).
All participants will be followed twice after baseline visit to re-evaluate and confirm the initial diagnosis (where applicable), and to record compliance to treatment scheme, including the process of medication titration.
This study does not recommend nor restrict any specific treatments.
3,678 studies on the registry are indexed under Alzheimer Disease; 872 are open to participants now.
This study's enrollment of 1,024 is above the median of 200 across 751 observational studies indexed under Alzheimer Disease.
Browse Alzheimer Disease studies →Peking University is the lead sponsor of 411 studies on the registry; 122 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Outpatients with clinically significant cognitive impairment per judgment of the participating physicians are registered.
Exclusion Criteria:
Outpatients with clinically significant cognitive impairment per judgment of the participating physicians are enrolled.
Rate of cognitive assessment administration
rate of cognitive assessment administration for diagnosing dementia
Time frame: 2 months
Rate of anti-dementia prescription
rate of anti-dementia prescription for people with dementia
Time frame: 2 months
compliance rate of anti-dementia prescription
rate of continuous using anti-dementia drugs among patients with dementia
Time frame: 2 months
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking University